Pediarix Vaccine Description
Pediarix contains diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and inactivated poliovirus vaccine.
Pediarix Vaccine Indication
Pediarix is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, and infection caused by all known subtypes of hepatitis B virus and poliomyelitis.
Pediarix Vaccine Dosage
Pediarix is approved for use as a three-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. Pediarix may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
Pediarix Vaccine News
December 31, 2020 - According to Reuters, for the new year, GSK plans to hike prices on two of their vaccines, Shingrix and Pediarix. These price increases are a direct result of the COVID-19 pandemic and the reduced number of doctor visits thus the reduced number of vaccinations given.
June 2, 2020 - COVID-19 Impact on Global Human Vaccines Market Size, Shares, Trends, Demands, Types, Applications & Key Industry Players - Sanofi Pasteur, Merck, Pfizer, AstraZeneca, Valneva, GSK, Seqirus
September 17, 2019 - Merck HepB vaccine shortage extended through mid-2020
Pediarix Clinical Trials
Clinical Trial NCT00146835: Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine
Clinical Trial NCT00133445: Pentavalent DTaP-Hep B-IPV
Clinical Trial NCT00879827: Immunogenicity and Reactogenicity of GSK Bio DTaP-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants